ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Galderma Group and Sun Pharmaceutical Industries side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Galderma GroupSun Pharmaceutical Industries
studies on the registry297328
open to participants now1211
phase 3 studies under way39
reach primary completion within a year85
programswith a study of their own in two years314

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGalderma GroupSun Pharmaceutical Industries
Phase 100%

Sun Pharmaceutical Industries: 10 of its 14 programs at phase 1

  1. DL2phase 1
  2. DL3phase 1
  3. DL4phase 1
  4. DL5phase 1
  5. Dose level (DL)1phase 1

and 5 more — sign in to see them all

71%
Phase 200%

Sun Pharmaceutical Industries: 1 of its 14 programs at phase 2

  1. utreglutidephase 2
7%
Phase 3

Galderma Group: 1 of its 3 programs at phase 3

  1. nemolizumabphase 3
33%

Sun Pharmaceutical Industries: 2 of its 14 programs at phase 3

  1. Deuruxolitinibphase 3
  2. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%phase 3
14%
Approved, new studies

Galderma Group: 2 of its 3 programs at approved, new studies

  1. trifaroteneapproved, new study
  2. cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotionapproved, new study
67%

Sun Pharmaceutical Industries: 1 of its 14 programs at approved, new studies

  1. Phenobarbitalapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Galderma Group2 readouts · 1 phase 3·

Galderma Group, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. nemolizumabphase 3 · Dec 0 · NCT07074977
  2. trifaroteneapproved, new study · Dec 31 · NCT07186413
··········
Sun Pharmaceutical Industries4 readouts · 2 phase 3·

Sun Pharmaceutical Industries, Dec ’26: 1 program whose next study reaches primary completion

  1. Drugs, Investigationalphase 1 · Dec 0 · NCT07729579

Sun Pharmaceutical Industries, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%phase 3 · Jan 0 · NCT07144345
··

Sun Pharmaceutical Industries, Apr ’27: 1 program whose next study reaches primary completion

  1. utreglutidephase 2 · Apr 0 · NCT07282743

Sun Pharmaceutical Industries, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Deuruxolitinibphase 3 · May 0 · NCT03898479
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Galderma Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Sun Pharmaceutical Industries

New programs 1

  • Phenobarbitalapproved, new study · first study · Oct 13 · Seizures

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionGalderma GroupSun Pharmaceutical Industries
Acne Vulgarisboth · compare here

Galderma Group in Acne Vulgaris: 1 program

  1. trifaroteneapproved, new study

Their studies: Galderma Group’s studies of Acne Vulgaris in search

Sun Pharmaceutical Industries in Acne Vulgaris: 3 programs

  1. Ivermectinphase 1
  2. Tretinoin Gel Microsphere, 0.04%phase 1
  3. trifarotenephase 1

Their studies: Sun Pharmaceutical Industries’ studies of Acne Vulgaris in search

Dermatitis, Atopicboth · compare here

Galderma Group in Dermatitis, Atopic: 1 program

  1. nemolizumabphase 3

Their studies: Galderma Group’s studies of Dermatitis, Atopic in search

Sun Pharmaceutical Industries in Dermatitis, Atopic: 2 programs

  1. Ivermectinphase 1
  2. tapinarofphase 1

Their studies: Sun Pharmaceutical Industries’ studies of Dermatitis, Atopic in search

Ichthyosis, Lamellarboth · compare here

Galderma Group in Ichthyosis, Lamellar: 1 program

  1. trifaroteneapproved, new study

Their studies: Galderma Group’s studies of Ichthyosis, Lamellar in search

Sun Pharmaceutical Industries in Ichthyosis, Lamellar: 1 program

  1. trifarotenephase 1

Their studies: Sun Pharmaceutical Industries’ studies of Ichthyosis, Lamellar in search

Psoriasisboth · compare here

Sun Pharmaceutical Industries in Psoriasis: 1 program

  1. tapinarofphase 1

Their studies: Sun Pharmaceutical Industries’ studies of Psoriasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetGalderma GroupSun Pharmaceutical Industries
RARGtrifaroteneruletrifarotenerule
A target, or a pathogen for a vaccine, known for: Galderma Group 2 of 3 · Sun Pharmaceutical Industries 3 of 14 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.